ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2026
Cross-reactive human antibody responses to H9N2 influenza virus, New York, United States, 2025.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding population immunity to emerging viruses is critical for risk assessment. We characterised antibody responses to avian influenza A(H9N2) viruses in 298 human sera from adults in New York City. We observed widespread cross-reactive H9-binding antibodies, albeit at lower levels (GMT = 371.3) than against seasonal H3 (GMT = 1,398.0), with low to undetectable haemagglutination inhibition and neutralising antibodies. In contrast, NA-binding and neuraminidase inhibition responses were moderate (GMT = 149.5 and 34.2) and comparable to those against human seasonal N2 (GMT = 259.0 and 42.2).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.